Immune Therapeutics, Inc. (IMUN) Steadfast in Effo
Post# of 39
Posted On: 03/30/2016 6:00:34 PM
Immune Therapeutics, Inc. (IMUN) Steadfast in Efforts Leveraging the Body’s Immune System on Continent of Africa
Immune Therapeutics, Inc. (OTCQB: IMUN) is positioned as a specialty pharmaceutical company focused on manufacturing, marketing and distributing novel patented therapies to fight chronic, life-threatening diseases. The company achieves this by way of the activation and modulation of the body’s immune system. Immune Therapeutics’ technology platform is built on two different immunotherapies, Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK). These therapies have required decades to develop thanks to work at institutions like the Pennsylvania State University Medical School at Hershey, the State University of New York, the University of Chicago, and the Multiple Sclerosis Center at UCSF. Spearheading efforts at these institutions were Dr. Nicholas Plotnikoff, Dr. Jaquelyn McCandless, Dr. Jill Smith, Dr. Ronald Herberman, Dr. Bernard Bihari, Ian S. Zagon, and Patricia McLaughlin.
Over the previous two years, IMUN has funneled its resources toward acquiring regulatory approval in emerging and developing nations for LDN, marketed under the brand name Lodonal™. Lodonal™ is considered a highly innovative immunotherapy for the treatment of HIV/AIDS, opportunistic infections, cancer and autoimmune diseases. The company’s proprietary Opiate and T Cell Receptor technology leverages the body’s immune system for identifying and killing diseased cells.
It has become widely known that African countries endure the greatest disease burden on the planet, with HIV/AIDS, TB and malaria being the highest threats. In addition to the burden developing nations are now experiencing, there is the additional burden of a rise in non-communicable diseases, including cancer, diabetes and inflammatory disease. Despite drugs being readily available in developing nations, the drugs are often too expensive and difficult to administer and cause significant side effects.
LDN is viewed as a solution to these problems. Existing treatments for cancer, HIV/AIDS, and autoimmune disease suppress the body’s immune system, while Lodonal (LDN) is an immune modulator used to rebalance or stimulate the immune system. The result is an improved quality of life for those who are inflicted with these diseases. The biggest treatment hurdle in developing nations is an inability to administer chemotherapy to people whose immune systems have been compromised. IMUN’s platform offsets this challenge by delivering affordable medications that are easy to administer.
Learn more by visiting www.immunetherapeutics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Immune Therapeutics, Inc. (OTCQB: IMUN) is positioned as a specialty pharmaceutical company focused on manufacturing, marketing and distributing novel patented therapies to fight chronic, life-threatening diseases. The company achieves this by way of the activation and modulation of the body’s immune system. Immune Therapeutics’ technology platform is built on two different immunotherapies, Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK). These therapies have required decades to develop thanks to work at institutions like the Pennsylvania State University Medical School at Hershey, the State University of New York, the University of Chicago, and the Multiple Sclerosis Center at UCSF. Spearheading efforts at these institutions were Dr. Nicholas Plotnikoff, Dr. Jaquelyn McCandless, Dr. Jill Smith, Dr. Ronald Herberman, Dr. Bernard Bihari, Ian S. Zagon, and Patricia McLaughlin.
Over the previous two years, IMUN has funneled its resources toward acquiring regulatory approval in emerging and developing nations for LDN, marketed under the brand name Lodonal™. Lodonal™ is considered a highly innovative immunotherapy for the treatment of HIV/AIDS, opportunistic infections, cancer and autoimmune diseases. The company’s proprietary Opiate and T Cell Receptor technology leverages the body’s immune system for identifying and killing diseased cells.
It has become widely known that African countries endure the greatest disease burden on the planet, with HIV/AIDS, TB and malaria being the highest threats. In addition to the burden developing nations are now experiencing, there is the additional burden of a rise in non-communicable diseases, including cancer, diabetes and inflammatory disease. Despite drugs being readily available in developing nations, the drugs are often too expensive and difficult to administer and cause significant side effects.
LDN is viewed as a solution to these problems. Existing treatments for cancer, HIV/AIDS, and autoimmune disease suppress the body’s immune system, while Lodonal (LDN) is an immune modulator used to rebalance or stimulate the immune system. The result is an improved quality of life for those who are inflicted with these diseases. The biggest treatment hurdle in developing nations is an inability to administer chemotherapy to people whose immune systems have been compromised. IMUN’s platform offsets this challenge by delivering affordable medications that are easy to administer.
Learn more by visiting www.immunetherapeutics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)Biostax Corp. (BTAX) Stock Research Links
Scroll down for more posts ▼